Skip to main content
Top
Published in: BMC Cancer 1/2019

Open Access 01-12-2019 | Cancer of Unknown Primary | Research article

Sarcomatoid carcinoma presenting as cancers of unknown primary: a clinicopathological portrait

Authors: Ryan W. Huey, Shalini Makawita, Lianchun Xiao, Aurelio Matamoros, Jeannelyn S. Estrella, Michael J. Overman, Gauri R. Varadhachary, Kanwal Raghav

Published in: BMC Cancer | Issue 1/2019

Login to get access

Abstract

Background

Sarcomatoid carcinoma of unknown primary (SCUP) is a rare entity of either poorly differentiated carcinoma with sarcoma-like differentiation or a true mixed lineage neoplasm. Limited data regarding clinicopathological profile and management exists.

Methods

We retrospectively reviewed the MD Anderson Cancer of Unknown Primary database and tumor registry to identify 48 SCUP patients between 2001 and 2017. Patient characteristics, pathology, molecular diagnostics, treatments, and outcomes were obtained. Kaplan-Meier method was used to estimate overall survival (OS) and compared using log rank test.

Results

Median age at diagnosis was 59 years (range 27–86). Majority of patients were female (58%) and presented with ≥3 metastatic sites (52%), commonly lymph node (50%), bone (42%), lung (27%), and liver (21%). First line treatment included chemotherapy (35%), surgery (27%), and radiation (24%). Gemcitabine and docetaxel (18%) was the most common chemotherapy regimen. Median OS for entire cohort was 11 months (95% CI: 5.6 to 16.4). Poor performance status (PS), > 1 metastatic site, elevated lactate dehydrogenase (LDH), and high neutrophil-to-lymphocyte ratio (NLR) were significantly associated with worse OS on univariate analyses. On multivariate analyses, poor PS (HR 8.7; 95%CI: 3.0–25.0; p <  0.001) and high NLR (HR 3.4; 95%CI: 1.3–8.8; p = 0.011) emerged as independent prognostic factors for OS.

Conclusions

SCUP is a rare presentation with an aggressive clinical course and limited survival. Diagnosis is difficult to make and requires careful review and synthesis of histology, immunohistochemistry, and molecular diagnostics. Chemotherapy resistance remains a challenge. Early mutational profiling is warranted, and clinical trial participation should be encouraged for this subset.
Appendix
Available only for authorised users
Literature
1.
go back to reference Briasoulis E, Tolis C, Bergh J, Pavlidis N, Force EGT. ESMO minimum clinical recommendations for diagnosis, treatment and follow-up of cancers of unknown primary site (CUP). Ann Oncol. 2005;16(Suppl 1):i75–6 PubMed PMID: 15888766. Epub 2005/05/13.CrossRefPubMed Briasoulis E, Tolis C, Bergh J, Pavlidis N, Force EGT. ESMO minimum clinical recommendations for diagnosis, treatment and follow-up of cancers of unknown primary site (CUP). Ann Oncol. 2005;16(Suppl 1):i75–6 PubMed PMID: 15888766. Epub 2005/05/13.CrossRefPubMed
2.
go back to reference Varadhachary GR, Raber MN. Cancer of unknown primary site. N Engl J Med. 2014;371(8):757–65 PubMed PMID: 25140961. Epub 2014/08/21.CrossRefPubMed Varadhachary GR, Raber MN. Cancer of unknown primary site. N Engl J Med. 2014;371(8):757–65 PubMed PMID: 25140961. Epub 2014/08/21.CrossRefPubMed
3.
go back to reference Zhang S, Jia J, Bi X, Jiang Q, Zhao Y, Chen Y, et al. Sarcomatoid carcinoma of the common bile duct: A case report. Medicine (Baltimore). 2017;96(3):e5751 PubMed PMID: 28099333. Pubmed Central PMCID: PMC5279078. Epub 2017/01/19.CrossRef Zhang S, Jia J, Bi X, Jiang Q, Zhao Y, Chen Y, et al. Sarcomatoid carcinoma of the common bile duct: A case report. Medicine (Baltimore). 2017;96(3):e5751 PubMed PMID: 28099333. Pubmed Central PMCID: PMC5279078. Epub 2017/01/19.CrossRef
4.
go back to reference Wang X, MacLennan GT, Zhang S, Montironi R, Lopez-Beltran A, Tan PH, et al. Sarcomatoid carcinoma of the upper urinary tract: clinical outcome and molecular characterization. Hum Pathol. 2009;40(2):211–7 PubMed PMID: 18799188. Epub 2008/09/19.CrossRefPubMed Wang X, MacLennan GT, Zhang S, Montironi R, Lopez-Beltran A, Tan PH, et al. Sarcomatoid carcinoma of the upper urinary tract: clinical outcome and molecular characterization. Hum Pathol. 2009;40(2):211–7 PubMed PMID: 18799188. Epub 2008/09/19.CrossRefPubMed
5.
go back to reference Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. J Clin Invest. 2009;119(6):1420–8 PubMed PMID: 19487818. Pubmed Central PMCID: PMC2689101. Epub 2009/06/03.CrossRefPubMedPubMedCentral Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. J Clin Invest. 2009;119(6):1420–8 PubMed PMID: 19487818. Pubmed Central PMCID: PMC2689101. Epub 2009/06/03.CrossRefPubMedPubMedCentral
6.
go back to reference Pang A, Carbini M, Moreira AL, Maki RG. Carcinosarcomas and related cancers: tumors caught in the act of epithelial-mesenchymal transition. J Clin Oncol. 2018;36(2):210–6 PubMed PMID: 29220296. Epub 2017/12/09.CrossRefPubMed Pang A, Carbini M, Moreira AL, Maki RG. Carcinosarcomas and related cancers: tumors caught in the act of epithelial-mesenchymal transition. J Clin Oncol. 2018;36(2):210–6 PubMed PMID: 29220296. Epub 2017/12/09.CrossRefPubMed
7.
go back to reference Raghav K, Mhadgut H, McQuade JL, Lei X, Ross A, Matamoros A, et al. Cancer of unknown primary in adolescents and young adults: Clinicopathological features, prognostic factors and survival outcomes. PLoS One. 2016;11(5):e0154985 PubMed PMID: 27171493. Pubmed Central PMCID: 4865168.CrossRefPubMedPubMedCentral Raghav K, Mhadgut H, McQuade JL, Lei X, Ross A, Matamoros A, et al. Cancer of unknown primary in adolescents and young adults: Clinicopathological features, prognostic factors and survival outcomes. PLoS One. 2016;11(5):e0154985 PubMed PMID: 27171493. Pubmed Central PMCID: 4865168.CrossRefPubMedPubMedCentral
8.
go back to reference Culine S, Kramar A, Saghatchian M, Bugat R, Lesimple T, Lortholary A, et al. Development and validation of a prognostic model to predict the length of survival in patients with carcinomas of an unknown primary site. J Clin Oncol. 2002;20(24):4679–83 PubMed PMID: 12488413.CrossRefPubMed Culine S, Kramar A, Saghatchian M, Bugat R, Lesimple T, Lortholary A, et al. Development and validation of a prognostic model to predict the length of survival in patients with carcinomas of an unknown primary site. J Clin Oncol. 2002;20(24):4679–83 PubMed PMID: 12488413.CrossRefPubMed
9.
go back to reference Greco FA, Erland JB, Morrissey LH, Burris HA 3rd, Hermann RC, Steis R, et al. Carcinoma of unknown primary site: phase II trials with docetaxel plus cisplatin or carboplatin. Ann Oncol. 2000;11(2):211–5 PubMed PMID: 10761758. Epub 2000/04/13.CrossRefPubMed Greco FA, Erland JB, Morrissey LH, Burris HA 3rd, Hermann RC, Steis R, et al. Carcinoma of unknown primary site: phase II trials with docetaxel plus cisplatin or carboplatin. Ann Oncol. 2000;11(2):211–5 PubMed PMID: 10761758. Epub 2000/04/13.CrossRefPubMed
10.
go back to reference Pouessel D, Culine S, Becht C, Romieu G, Fabbro M, Ychou M, et al. Gemcitabine and docetaxel after failure of cisplatin-based chemotherapy in patients with carcinoma of unknown primary site. Anticancer Res. 2003;23(3C):2801–4 PubMed PMID: 12926116. Epub 2003/08/21.PubMed Pouessel D, Culine S, Becht C, Romieu G, Fabbro M, Ychou M, et al. Gemcitabine and docetaxel after failure of cisplatin-based chemotherapy in patients with carcinoma of unknown primary site. Anticancer Res. 2003;23(3C):2801–4 PubMed PMID: 12926116. Epub 2003/08/21.PubMed
11.
go back to reference Culine S, Lortholary A, Voigt JJ, Bugat R, Theodore C, Priou F, et al. Cisplatin in combination with either gemcitabine or irinotecan in carcinomas of unknown primary site: results of a randomized phase II study--trial for the French study group on carcinomas of unknown primary (GEFCAPI 01). J Clin Oncol. 2003;21(18):3479–82 PubMed PMID: 12972523. Epub 2003/09/16.CrossRefPubMed Culine S, Lortholary A, Voigt JJ, Bugat R, Theodore C, Priou F, et al. Cisplatin in combination with either gemcitabine or irinotecan in carcinomas of unknown primary site: results of a randomized phase II study--trial for the French study group on carcinomas of unknown primary (GEFCAPI 01). J Clin Oncol. 2003;21(18):3479–82 PubMed PMID: 12972523. Epub 2003/09/16.CrossRefPubMed
12.
go back to reference Briasoulis E, Kalofonos H, Bafaloukos D, Samantas E, Fountzilas G, Xiros N, et al. Carboplatin plus paclitaxel in unknown primary carcinoma: a phase II Hellenic cooperative oncology group study. J Clin Oncol. 2000;18(17):3101–7 PubMed PMID: 10963638. Epub 2000/08/30.CrossRefPubMed Briasoulis E, Kalofonos H, Bafaloukos D, Samantas E, Fountzilas G, Xiros N, et al. Carboplatin plus paclitaxel in unknown primary carcinoma: a phase II Hellenic cooperative oncology group study. J Clin Oncol. 2000;18(17):3101–7 PubMed PMID: 10963638. Epub 2000/08/30.CrossRefPubMed
13.
go back to reference O’Callaghan DS, O’Donnell D, O’Connell F, O’Byrne KJ. The role of inflammation in the pathogenesis of non-small cell lung cancer. J Thorac Oncol. 2010;5(12):2024–36 PubMed PMID: 21155185. Epub 2010/12/16.CrossRefPubMed O’Callaghan DS, O’Donnell D, O’Connell F, O’Byrne KJ. The role of inflammation in the pathogenesis of non-small cell lung cancer. J Thorac Oncol. 2010;5(12):2024–36 PubMed PMID: 21155185. Epub 2010/12/16.CrossRefPubMed
14.
go back to reference Templeton AJ, McNamara MG, Seruga B, Vera-Badillo FE, Aneja P, Ocana A, et al. Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. J Natl Cancer Inst. 2014;106(6):dju124 PubMed PMID: 24875653. Epub 2014/05/31.CrossRefPubMed Templeton AJ, McNamara MG, Seruga B, Vera-Badillo FE, Aneja P, Ocana A, et al. Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. J Natl Cancer Inst. 2014;106(6):dju124 PubMed PMID: 24875653. Epub 2014/05/31.CrossRefPubMed
15.
go back to reference Kobayashi M, Kubo T, Komatsu K, Fujisaki A, Terauchi F, Natsui S, et al. Changes in peripheral blood immune cells: their prognostic significance in metastatic renal cell carcinoma patients treated with molecular targeted therapy. Med Oncol. 2013;30(2):556 PubMed PMID: 23539200. Epub 2013/03/30.CrossRefPubMed Kobayashi M, Kubo T, Komatsu K, Fujisaki A, Terauchi F, Natsui S, et al. Changes in peripheral blood immune cells: their prognostic significance in metastatic renal cell carcinoma patients treated with molecular targeted therapy. Med Oncol. 2013;30(2):556 PubMed PMID: 23539200. Epub 2013/03/30.CrossRefPubMed
16.
go back to reference Abe T, Amano H, Kobayashi T, Hanada K, Nakahara M, Ohdan H, et al. Preoperative neutrophil-to-lymphocyte ratio as a prognosticator in early stage pancreatic ductal adenocarcinoma. Eur J Surg Oncol. 2018;44(10):1573–9 PubMed PMID: 29807728. Epub 2018/05/29.CrossRefPubMed Abe T, Amano H, Kobayashi T, Hanada K, Nakahara M, Ohdan H, et al. Preoperative neutrophil-to-lymphocyte ratio as a prognosticator in early stage pancreatic ductal adenocarcinoma. Eur J Surg Oncol. 2018;44(10):1573–9 PubMed PMID: 29807728. Epub 2018/05/29.CrossRefPubMed
17.
go back to reference Lorente D, Mateo J, Templeton AJ, Zafeiriou Z, Bianchini D, Ferraldeschi R, et al. Baseline neutrophil-lymphocyte ratio (NLR) is associated with survival and response to treatment with second-line chemotherapy for advanced prostate cancer independent of baseline steroid use. Ann Oncol. 2015;26(4):750–5 PubMed PMID: 25538172. Epub 2014/12/30.CrossRefPubMed Lorente D, Mateo J, Templeton AJ, Zafeiriou Z, Bianchini D, Ferraldeschi R, et al. Baseline neutrophil-lymphocyte ratio (NLR) is associated with survival and response to treatment with second-line chemotherapy for advanced prostate cancer independent of baseline steroid use. Ann Oncol. 2015;26(4):750–5 PubMed PMID: 25538172. Epub 2014/12/30.CrossRefPubMed
18.
go back to reference Cedres S, Torrejon D, Martinez A, Martinez P, Navarro A, Zamora E, et al. Neutrophil to lymphocyte ratio (NLR) as an indicator of poor prognosis in stage IV non-small cell lung cancer. Clin Transl Oncol. 2012;14(11):864–9 PubMed PMID: 22855161. Epub 2012/08/03.CrossRefPubMed Cedres S, Torrejon D, Martinez A, Martinez P, Navarro A, Zamora E, et al. Neutrophil to lymphocyte ratio (NLR) as an indicator of poor prognosis in stage IV non-small cell lung cancer. Clin Transl Oncol. 2012;14(11):864–9 PubMed PMID: 22855161. Epub 2012/08/03.CrossRefPubMed
19.
go back to reference Kiriu T, Yamamoto M, Nagano T, Hazama D, Sekiya R, Katsurada M, et al. The time-series behavior of neutrophil-to-lymphocyte ratio is useful as a predictive marker in non-small cell lung cancer. PLoS One. 2018;13(2):e0193018 PubMed PMID: 29447258. Pubmed Central PMCID: PMC5814002. Epub 2018/02/16.CrossRefPubMedPubMedCentral Kiriu T, Yamamoto M, Nagano T, Hazama D, Sekiya R, Katsurada M, et al. The time-series behavior of neutrophil-to-lymphocyte ratio is useful as a predictive marker in non-small cell lung cancer. PLoS One. 2018;13(2):e0193018 PubMed PMID: 29447258. Pubmed Central PMCID: PMC5814002. Epub 2018/02/16.CrossRefPubMedPubMedCentral
20.
go back to reference Terra SB, Aubry MC, Yi ES, Boland JM. Immunohistochemical study of 36 cases of pulmonary sarcomatoid carcinoma--sensitivity of TTF-1 is superior to napsin. Hum Pathol. 2014;45(2):294–302 PubMed PMID: 24331839. Epub 2013/12/18.CrossRefPubMed Terra SB, Aubry MC, Yi ES, Boland JM. Immunohistochemical study of 36 cases of pulmonary sarcomatoid carcinoma--sensitivity of TTF-1 is superior to napsin. Hum Pathol. 2014;45(2):294–302 PubMed PMID: 24331839. Epub 2013/12/18.CrossRefPubMed
21.
go back to reference Economopoulou P, Mountzios G, Pavlidis N, Pentheroudakis G. Cancer of unknown primary origin in the genomic era: elucidating the dark box of cancer. Cancer Treat Rev. 2015;41(7):598–604 PubMed PMID: 26033502. Epub 2015/06/03.CrossRefPubMed Economopoulou P, Mountzios G, Pavlidis N, Pentheroudakis G. Cancer of unknown primary origin in the genomic era: elucidating the dark box of cancer. Cancer Treat Rev. 2015;41(7):598–604 PubMed PMID: 26033502. Epub 2015/06/03.CrossRefPubMed
22.
go back to reference Ross JS, Wang K, Gay L, Otto GA, White E, Iwanik K, et al. Comprehensive genomic profiling of carcinoma of unknown primary site: new routes to targeted therapies. JAMA Oncol. 2015;1(1):40–9 PubMed PMID: 26182302. Epub 2015/07/17.CrossRefPubMed Ross JS, Wang K, Gay L, Otto GA, White E, Iwanik K, et al. Comprehensive genomic profiling of carcinoma of unknown primary site: new routes to targeted therapies. JAMA Oncol. 2015;1(1):40–9 PubMed PMID: 26182302. Epub 2015/07/17.CrossRefPubMed
23.
go back to reference Le DT, Durham JN, Smith KN, Wang H, Bartlett BR, Aulakh LK, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science. 2017;357(6349):409–13 PubMed PMID: 28596308. Pubmed Central PMCID: PMC5576142. Epub 2017/06/10.CrossRefPubMedPubMedCentral Le DT, Durham JN, Smith KN, Wang H, Bartlett BR, Aulakh LK, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science. 2017;357(6349):409–13 PubMed PMID: 28596308. Pubmed Central PMCID: PMC5576142. Epub 2017/06/10.CrossRefPubMedPubMedCentral
24.
go back to reference Arumugam T, Ramachandran V, Fournier KF, Wang H, Marquis L, Abbruzzese JL, et al. Epithelial to mesenchymal transition contributes to drug resistance in pancreatic cancer. Cancer Res. 2009;69(14):5820–8 PubMed PMID: 19584296. Pubmed Central PMCID: PMC4378690.CrossRefPubMedPubMedCentral Arumugam T, Ramachandran V, Fournier KF, Wang H, Marquis L, Abbruzzese JL, et al. Epithelial to mesenchymal transition contributes to drug resistance in pancreatic cancer. Cancer Res. 2009;69(14):5820–8 PubMed PMID: 19584296. Pubmed Central PMCID: PMC4378690.CrossRefPubMedPubMedCentral
25.
go back to reference Zhang W, Feng M, Zheng G, Chen Y, Wang X, Pen B, et al. Chemoresistance to 5-fluorouracil induces epithelial-mesenchymal transition via up-regulation of snail in MCF7 human breast cancer cells. Biochem Biophys Res Commun. 2012;417(2):679–85 PubMed PMID: 22166209.CrossRefPubMed Zhang W, Feng M, Zheng G, Chen Y, Wang X, Pen B, et al. Chemoresistance to 5-fluorouracil induces epithelial-mesenchymal transition via up-regulation of snail in MCF7 human breast cancer cells. Biochem Biophys Res Commun. 2012;417(2):679–85 PubMed PMID: 22166209.CrossRefPubMed
26.
go back to reference Davis FM, Stewart TA, Thompson EW, Monteith GR. Targeting EMT in cancer: opportunities for pharmacological intervention. Trends Pharmacol Sci. 2014;35(9):479–88 PubMed PMID: 25042456.CrossRefPubMed Davis FM, Stewart TA, Thompson EW, Monteith GR. Targeting EMT in cancer: opportunities for pharmacological intervention. Trends Pharmacol Sci. 2014;35(9):479–88 PubMed PMID: 25042456.CrossRefPubMed
Metadata
Title
Sarcomatoid carcinoma presenting as cancers of unknown primary: a clinicopathological portrait
Authors
Ryan W. Huey
Shalini Makawita
Lianchun Xiao
Aurelio Matamoros
Jeannelyn S. Estrella
Michael J. Overman
Gauri R. Varadhachary
Kanwal Raghav
Publication date
01-12-2019
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2019
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-019-6155-6

Other articles of this Issue 1/2019

BMC Cancer 1/2019 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine